Arindam Talukdar

Dr. Arindam Talukdar

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
SPSourav Pal
Sourav Pal
Vinay KumarVinay Kumar
Vinay Kumar
BKBiswajit Kundu
Biswajit Kundu
DBDebomita Bhattacharya
Debomita Bhattacharya
NPNagothy Preethy
Nagothy Preethy
ATArindam Talukdar
Arindam Talukdar
Camptothecin (CPT), a natural product and its synthetic derivatives exert potent anticancer activity by selectively targeting DNA Topoisomerase I (Top1) enzyme. CPT and its clinically approved derivatives are used as Top1 poisons for cancer therapy suffer from many limitations related to stability and toxicity. In order to envisage structurally diverse novel chemical entity as Top1 poison with better efficacy, Ligand-based-pharmacophore model was developed using 3D QSAR pharmacophore generation (HypoGen algorithm) methodology in Discovery studio 4.1 clients. The chemical features of 29 CPT derivatives were taken as the training set. The selected pharmacophore model Hypo1 was further validated by 33 test set molecules and used as a query model for further screening of 1,087,724 drug-like molecules from ZINC databases. These molecules were subjected to several assessments such as Lipinski rule of 5, SMART filtration and activity filtration. The molecule obtained after filtration was further scrutinized by molecular docking analysis on the active site of Top1 crystal structure (PDB ID: 1T8I). Six potential inhibitory molecules have been selected by analyzing the binding interaction and Ligand-Pharmacophore mapping with the validated pharmacophore model. Toxicity assessment TOPKAT program provided three potential inhibitory 'hit molecules' ZINC68997780, ZINC15018994 and ZINC38550809. MD simulation of these three molecules proved that the ligand binding into the protein-DNA cleavage complex is stable and the protein-ligands conformation remains unchanged. These three hit molecules can be utilized for designing future class of potential topoisomerase I inhibitor.

2 April 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ATArindam Talukdar
Arindam Talukdar
BKBiswajit Kundu
Biswajit Kundu
DSDipayan Sarkar
Dipayan Sarkar
SGSunny Goon
Sunny Goon
MMMohabul Alam Mondal
Mohabul Alam Mondal

21 March 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BKBiswajit Kundu
Biswajit Kundu
SDSubhendu Kumar Das
Subhendu Kumar Das
SCSrijita Paul Chowdhuri
Srijita Paul Chowdhuri
SPSourav Pal
Sourav Pal
DSDipayan Sarkar
Dipayan Sarkar
ATArindam Talukdar
Arindam Talukdar

9 June 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ATArindam Talukdar
Arindam Talukdar
DGDipyaman Ganguly
Dipyaman Ganguly
SRSwarnali Roy
Swarnali Roy
NDNirmal Das
Nirmal Das
DSDipika Sarkar
Dipika Sarkar

22 April 2019 in ACS Omega
Verified
Journal Article
Open access
AMAyan Mukherjee
Ayan Mukherjee
SMSnehasis Mishra
Snehasis Mishra
NKNaveen Kumar Kotla
Naveen Kumar Kotla
KMKrishnendu Manna
Krishnendu Manna
SRSwarnali Roy
Swarnali Roy
ATArindam Talukdar
Arindam Talukdar
Quercetin has been found to possess diverse pharmacological properties including in different types of cancers. The application of quercetin in the pharmaceutical field is limited due to its poor bioavailability resulting from poor water solubility and poor permeability. We report a systematic chemical modification of quercetin toward the development of semisynthetic derivatives through a selective synthetic methodology, which enables the installation of different substitutions at C-3′ and C-5 positions of quercetin. The hypothesis of the present manuscript was to modulate the log D value and aqueous solubility of quercetin through the attachment of some facilitator moieties. The semisynthetic derivatives with an ideal log D value and improved aqueous solubility will possess a better cell-penetrating ability compared to quercetin. Representative compound 17 shows 96-fold increase in the cytotoxic activity in HCT-116 colon cancer cells as compared to quercetin. The in vivo treatment of 17 in CT-26 tumor-bearing mice in a colon cancer model resulted in a striking increase in the survival rate and reduction in tumor weight (60%) with respect to quercetin. We believe that the current study has an immense potential toward the systemic development of clinically approved quercetin semisynthetic derivatives.

17 April 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AMAyan Mukherjee
Ayan Mukherjee
DRDeblina Raychaudhuri
Deblina Raychaudhuri
BSBishnu Prasad Sinha
Bishnu Prasad Sinha
BKBiswajit Kundu
Biswajit Kundu
MMMousumi Mitra
Mousumi Mitra
ATArindam Talukdar
Arindam Talukdar